Epithalon
LongevityEpithalon is the longevity-research community's quiet workhorse. A four-amino-acid pineal-derived peptide developed across thirty years of Russian gerontological research, it influences telomerase, pineal rhythm, and — in the longest-running human studies of any peptide therapeutic — measurable changes in age-related mortality curves. The interesting thing is not its potency in any one direction but how many of the hallmarks of aging it touches at once.
Key Takeaways
Identified by Khavinson; 15-year human follow-up studies are among the longest-running in peptide research. Mechanism touches telomerase activation, pineal melatonin restoration, and putative epigenetic clock effects. Cycle-based dosing (10–20 days, 1–2× per year) is the canonical protocol — not continuous use. Pairs cleanly with thymalin (the original Khavinson combination), pinealon, and NAD+. Outstanding safety record across decades of clinical observation; no significant adverse events reported.
The hallmarks-of-aging framework gives us a way to evaluate longevity interventions by which biological dimensions they engage. Few peptides touch as many at once as epithalon — not by being a powerful agonist of any single pathway but by acting on the upstream regulatory peptides that influence many.
Telomerase activation and telomere length
Epithalon upregulates telomerase reverse transcriptase activity in somatic cells, producing measurable increases in telomere length in long-cycle human studies. This addresses the genomic instability hallmark of aging directly. Telomere lengthening is not by itself proof of biological rejuvenation — telomere length is a noisy biomarker — but the direction of effect over multi-year follow-up is consistent.
Pineal restoration and circadian biology
The pineal gland's melatonin output declines steeply with age, and that decline drives downstream consequences in sleep architecture, circadian metabolism, and immune cycling. Epithalon was originally developed precisely to restore pineal function. The downstream effects on sleep quality and night-time hormone profiles are among the most consistent subjective reports across longevity-focused users.
Putative epigenetic clock effects
The most interesting and least settled mechanism. Animal and small human studies suggest epithalon influences DNA methylation patterns at sites that contribute to the Horvath, Hannum, and PhenoAge epigenetic clocks. If durable, this places epithalon among a small set of interventions with documented effects on biological age markers. Larger human trials with paired methylation profiling are an active research direction.
Canonical use case. Annual or biannual 10–20 day cycles produce changes in melatonin profile, immune function markers, and — in long-running cohort data — measurable shifts in age-related mortality curves over multi-year follow-up. The protocol pattern is closer to a periodic biological reset than to a daily supplement.
The subjective signal users most often report: deeper sleep, more consistent sleep onset, and a clearer waking state. Particularly relevant in mid-late adulthood when pineal melatonin output naturally declines.
Used periodically in longevity protocols alongside thymalin, pinealon, and NAD+ as the 'cycle stack' — short, periodic peptide bursts that influence the regulatory layer above hormone and immune function.
Some users now track DNA methylation age (Horvath, PhenoAge, GrimAge) before and after epithalon cycles. The literature is preliminary but the direction of effect is encouraging — enough to make this one of the few peptide protocols where biological-age testing is a reasonable outcome metric.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Annual longevity cycle | SubQ | 5–10 mg | Daily × 10–20 days, 1–2× yearly |
| Biannual maintenance | SubQ | 5 mg | Daily × 10 days, every 6 months |
| Intranasal cycle | Intranasal | 200–400 mcg per spray | Daily × 10–20 days, 1–2× yearly |
| Khavinson combination | SubQ | Epithalon 5–10 mg + Thymalin 5–10 mg | Alternating days × 20 days |
Pulsatile, cycle-based dosing is the longevity-research convention. Daily continuous use is not supported by the underlying mechanism (or by the published protocols) and may downregulate the same systems it is meant to support. Two cycles per year, separated by 4–6 months, is the typical pattern.
Longevity stacks are designed to address several hallmarks of aging in parallel — telomere maintenance, mitochondrial function, pineal rhythm, immune resilience, and epigenetic regulation. Epithalon contributes the pineal-telomere-epigenetic layer; companion peptides cover the others.
- Epithalon + Thymalin: The original Khavinson combination. Thymalin addresses immune senescence; epithalon addresses pineal and telomere maintenance. The 15-year Russian outcome data is largely from this combination.
- Epithalon + Pinealon: Two pineal-region peptides with complementary effects: epithalon's tetrapeptide for pineal rhythm and telomerase; pinealon's tripeptide for neuroprotection. Stacked during longevity cycles.
- Epithalon + NAD+: Combines pineal-melatonin restoration with sirtuin substrate replenishment. Two of the most evidence-supported levers in the NAD-and-aging literature.
- Epithalon + GHK-Cu: Adds the gene-expression-modulating layer (GHK-Cu has documented effects on >4,000 genes). Used in longevity-focused users prioritising skin, connective tissue, and broader cellular reprogramming.
- Avoid stacking with melatonin during cycle: Epithalon's pineal restoration may produce supraphysiological circulating melatonin if exogenous melatonin is simultaneously dosed. Pause exogenous melatonin during cycles to allow the endogenous restoration to be visible.
Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard.
Epithalon has one of the cleanest safety records in peptide therapeutics, with multi-decade Russian clinical observation and 15-year human follow-up showing no significant adverse events. The cycle-based dosing pattern further reduces any theoretical long-term concern. The main consideration for longevity-focused users is to maintain the cycle structure rather than drift into continuous daily use, which would be both pharmacologically illogical and depart from the protocol on which the safety data is based.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Epithalon | Pineal / telomere / epigenetic | Cycle-based (10–20 days) | Pineal restoration, telomere, biological age |
| Thymalin | Thymic / immune senescence | Cycle-based | Immune restoration, T-cell function |
| MOTS-c | Mitochondrial / AMPK | Weeks | Mitochondrial biogenesis, insulin sensitivity |
| GHK-Cu | Gene expression / collagen | Weeks | Skin, connective tissue, wound healing |
| NAD+ | Sirtuin substrate / redox | Days | Sirtuin function, energy metabolism |
Does epithalon actually extend lifespan?
How do I know if it is working?
Can I use it continuously instead of in cycles?
When in life should I start?
Is intranasal as effective as injection?
Will it interfere with my regular sleep schedule?
Start a Epithalon Protocol
Alukard provides physician-supervised longevity protocols with GMP-certified Epithalon and GMP-certified compounds with biological age testing and healthspan markers.
Get ProtocolQuick Facts
- Molecular weight
- 390 Da
- Sequence length
- 4 aa
- Half-life
- Very short (minutes)
- WADA
- Not specifically listed
- FDA
- Unapproved
- Research
- Multi-decade Russian research; long-running human cohort studies
All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Epithalon unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Longevity / Hallmarks of Aging Protocol for Epithalon
Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.
HIPAA Compliant · GMP Certified · Physician Supervised